Medically reviewed by Dr. Noor Hussam Abu-Farsakh — Gastroenterologist & Hepatologist
Fatty liver is the build-up of fat in liver cells. It is now the most common liver disease, closely linked to excess weight, diabetes and high lipids, and is now called metabolic dysfunction-associated steatotic liver disease (MASLD). Most cases are mild, but some progress to inflammation and fibrosis if untreated.
Who is at risk?
- Excess weight, especially around the waist.
- Type 2 diabetes or insulin resistance.
- High triglycerides or cholesterol.
- High blood pressure.
Symptoms
Usually none — fatty liver is often found by chance on ultrasound or raised liver enzymes. Some people feel tired or a heaviness in the upper right abdomen.
How is it assessed?
The key question is not the fat itself but the degree of fibrosis. This is estimated with simple blood-test scores (such as FIB-4) and, when needed, liver stiffness measurement (FibroScan).
Treatment
Lifestyle change is the cornerstone: losing 7–10% of body weight clearly improves fat and inflammation, and may improve fibrosis. A balanced diet (such as Mediterranean), fewer sugars and sweet drinks, and at least 150 minutes of activity a week are recommended.
Controlling diabetes, lipids and blood pressure is essential, and medication is used in selected cases.
When to see a liver specialist
- Persistently raised liver enzymes.
- Tests suggesting fibrosis.
- Diabetes with fatty liver.
- Yellow eyes, abdominal or leg swelling.
- Fatty liver is common and often silent, but reversible.
- Assessing fibrosis matters more than the fat itself.
- Gradual weight loss and exercise are the most important treatment.
This article is for health education and does not replace medical advice.
References
- EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492–542.
- Rinella ME, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797–1835.
- Rinella ME, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023.

